Anhui HygeianCells EE001 vs CardiAMP
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Heart Failure
Shared mechanism: Cardiac cell therapy · full Heart Failure pipeline
Anhui HygeianCells EE001
Developed by Anhui HygeianCells BioMedical
NCT06884111 · Phase 1 · completed
Only 6 people received the drug, all in a single open, unblinded group with no placebo or comparison arm, so any change seen cannot be attributed to the drug with confidence. No results have been posted yet.
No aligned efficacy figure on record for this race.
CardiAMP
Developed by BioCardia
NCT02438306 · Phase 3 · completed
The study randomized 125 participants to CardiAMP or a sham procedure and masked participants and outcome assessors. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: April 2027 · NCT06258447 (registry estimate)
Reported efficacy
A composite endpoint based on a 3-tiered Finkelstein-Schoenfeld (FS) hierarchical analysis. (12 Months): 3-tiered Finkelstein-Schoenfeld primary endpoint at 12 months (interim, 102 of eventual 125 patients): Tier 1 all-cause death 5.6% CardiAMP vs 5.3% control (P=.42); Tier 2 MACCE 16.7% vs 15.8% (P=.82); Tier 3 6MWT change +36.1m vs +33.4m (P=.6) - none reached significance; DSMB futility review concluded the trial was unlikely to meet its primary endpoint (missed)
Result source: NCT02438306
Results for Heart Failure
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Anhui HygeianCells EE001 | CardiAMP |
|---|---|---|
| CV death or HF hospitalisation | —Not reported | —Not posted · NCT02438306 |
| HF hospitalisation | —Not reported | —Not posted · NCT02438306 |
| CV death | —Not reported | —Not posted · NCT02438306 |
| KCCQ clinical summary, change | —Not reported | —Not posted · NCT02438306 |
CV death or HF hospitalisation
- Anhui HygeianCells EE001
- —Not reported
- CardiAMP
- —Not posted · NCT02438306
HF hospitalisation
- Anhui HygeianCells EE001
- —Not reported
- CardiAMP
- —Not posted · NCT02438306
CV death
- Anhui HygeianCells EE001
- —Not reported
- CardiAMP
- —Not posted · NCT02438306
KCCQ clinical summary, change
- Anhui HygeianCells EE001
- —Not reported
- CardiAMP
- —Not posted · NCT02438306
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Anhui HygeianCells EE001: no structured comparison results are available for Heart Failure.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
CardiAMP
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Anhui HygeianCells EE001's landscape · CardiAMP's landscape